LC method for the analysis of Oxiconazole in pharmaceutical formulations.
A LC method has been developed for the quantitative determination of Oxiconazole (Ox) in bulk form, lotion and cream pharmaceutical formulations. The method validation yielded good results including the range, linearity, precision, accuracy, recovery, specificity, robustness, limit of quantitation and limit of detection. The LC separation was carried by reversed phase chromatography using a LiChrocart C(8) column (125 mm x 4.0 mm i.d., 5 microm particle size). The mobile phase was composed of methanol-0.02 M ammonium acetate buffer (85:15 v/v), pumped isocratically at flow rate 1 ml min(-1). The detection was carried out on UV detector at 254 nm. The calibration curve for Ox was linear from 40.0-140.0 microg ml(-1) range. The precision of this method, calculated as the relative standard deviation (R.S.D.) was 1.57% for lotion and 0.71% for cream. The R.S.D. values for intra- and inter-day precision studies were 0.57 and 1.34%, respectively. The recovery of the drug ranged between 98.84-102.2% (lotion) and 100.54-101.59% (cream). The stability indicating capability of the assays was proved using forced degradation. Chromatograms showed Ox well resolved from the degradation product.
Sensitive gas-liquid chromatographic method for the determination of oxiconazole in plasma.
A specific and highly sensitive gas-liquid chromatographic method was developed for the determination of oxiconazole in rat, dog, and human plasma. The compound and its internal standard were extracted from plasma at basic pH with n-hexane-isoamyl alcohol (98:2, v/v), gas chromatographed on 3% SP-2250/Supelcoport (80-100 mesh) and quantified by means of an electron-capture detector. Oxiconazole was extracted almost quantitatively from plasma in the concentration range 10-5000 ng/ml. The sensitivity limit was about 1 ng/ml, using a 1-ml specimen. The method was applied to 13-week tolerance studies in dogs and rats in order to follow oxiconazole concentrations in plasma after oral administration of the compound. The assay was sensitive enough to measure precisely the small amounts of unchanged compound in plasma after intravaginal application of labelled oxiconazole to human volunteers.
Interaction of Diclofop-Methyl and MCPA on Wild Oats (Avena fatua)
Diclofop-methyl {methyl 2-[4-(2,4-dichlorophenoxy)phenoxy] propanoate} loses part of its activity on wild oats (Avena fatua L.) when it is applied in combination with ester or amine formulations of MCPA {[4-chloro-o-tolyl)oxy] acetic acid.} Uptake of diclofop-methyl is reduced in the presence of commercial formulations of MCPA, particularly amine formulations, which are only partly compatible with the diclofop-methyl formulation. With added MCPA, regardless of formulation, hydrolysis of diclofop-methyl to the acid diclofop is slowed down, both in intact wild oat plants and in a crude leaf extract. At the same time, conversion of any acid formed to inactive conjugates is accelerated in the presence of MCPA. It is concluded that the loss of activity of diclofop-methyl by MCPA can be accounted for by the effects of MCPA on uptake and metabolic conversion of diclofop-methyl.